Does liver stiffness measurement predict severe portal hypertension in patients with HCV-related cirrhosis?
LSM represents a non-invasive tool for the identification of chronic liver disease patients with clinically significant or severe portal hypertension and could be employed for screening patients to be subjected to standard investigations including upper GI endoscopy and hemodynamic studies.
These findings indicated that M(3)-mAChR upregulates HO-1 and VEGF expression likely through induction of HIF-1α, which at least partly underlies the cytoprotection of M(3)-mAChR activation in H9c2 cells.